Home > Insider Trading > Filing (0001209191-22-052799)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840574	Verve Therapeutics Inc.	VERV	Pharmaceutical Preparations (2834)	824800132

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1864112	Sekar Kathiresan	C/O Verve Therapeutics 500 Technology Square, Suite 901 Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-10-03	50,000	$1.39	367,839	No	4	M	Direct
Common Stock	Disposition	2022-10-03	28,911	$33.02	338,928	No	4	S	Direct
Common Stock	Disposition	2022-10-03	11,185	$34.13	327,743	No	4	S	Direct
Common Stock	Disposition	2022-10-03	9,904	$34.97	317,839	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2022-10-03	50,000	$0.00	50,000	$1.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
138,995		2029-04-14	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	240,997	Indirect	Kathiresan Family 2021 Irrevocable Trust
Common Stock	80,997	Indirect	Sekar Kathiresan 2021 Irrevocable Trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive.
The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024.